Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D & Thomforde, G. (2004)

Clin Gastroenterol Hepatol; 2: 895–904

View article

Circulating soluble adhesion molecules in inflammatory bowel disease

Patel, Pall et al

Eur J Gastroenterol Hepatatol 1995 7;11; 1037-1041

View abstract

Spontaneous aggregation of leukocytes in active ulcerative colitis might be ICAM-1 dependent

Vainer B, Berliner S, Nielsen OH

Inflammation Research Birkhäuser Verlag, Basel, 2004

View article

Ulcerative Colitis

Ingrid Ordas, Lars Eckmann, Mark Talamini, Daniel C Baumgart, William J Sandborn

Lancet 2012; 380: 1606-19

View article

The Long March of Antisense

Dan Jones

Nature Reviews: Vol . 10 June 2011

View article

Alicaforsen for the treatment of inflammatory bowel disease

V. Jairath, R. Khanna, B.G. Feagan

Expert Opin Investig Drugs 2017 Jul 6:1-7

View article

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

S.J.H. Van Deventer, J.A. Tami, M.K. Wedel, European Colitis Study Group

Gut (2004) 53: 1646-1651

View article

Bioavailability and therapeutic activity of alicaforsen administered as a rectal retention enema to subjects with active ulcerative colitis

P.B. Miner JR, R.S.Geary, J. Matson, E. Chuang, S. Xia, B.F. Baker & M.K. Wedel

Aliment Pharmacol Ther (2006) 23: 1427-1434

View article


The information in “published papers” is provided by Atlantic Healthcare plc, and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.